{
    "nct_id": "NCT04407247",
    "official_title": "Treatment of Immune Checkpoint Inhibitor-Related Colitis With Infliximab or Vedolizumab: A Randomized Trial",
    "inclusion_criteria": "* Patients who receive any type of immune checkpoint inhibitor (ICI) therapy\n* Patients with peak grade >= 2 immune-related diarrhea and/or colitis (according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 within 45 days prior to initiation of study treatment (infliximab/ vedolizumab)\n* Patients with ability to understand and willingness to sign informed consent\n* Patients with genitourinary cancer or melanoma or non-small cell lung cancer\n* No concern for active concomitant GI infection for immune-related diarrhea and/or colitis work up at the time of protocol therapy initiation as confirmed by stool tests or as per the treating physician based on clinical presentation\n* Patient who has been cleared for enrollment by Infectious Diseases consultant or treating physician if positive infection workup or screening tests (e.g. lifelong positive T-spot due to BCG inoculation, chronic colonization) prior to initiation of diarrhea/colitis treatment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients younger than 18 years of age\n* Patients with persistent gastrointestinal infection confirmed with positive testing despite completing 5 days of antibiotics\n* Patients are on concurrent immunosuppressive therapies other than what will be given for colitis\n* Patients with preexisting activehistory of inflammatory bowel disease and/or radiation enterocolitis with active disease status at the time of study treatment initiation\n* Pregnant and breastfeeding women, and\n* Women of child-bearing potential who have positive urine or serum pregnancy test or refuse to do pregnancy test unless last menstrual cycle was > 1 year prior to consent and/ or clear documentation states that patient is peri- or post-menopausal or there was recent supporting objective evidence of 'no pregnancy' status (e.g. blood or imaging) within 30 days prior to initiation of study treatment\n* Patients who develop concurrent non-GI toxicity at the time of study treatment initiation",
    "miscellaneous_criteria": ""
}